Psychedelic Treatments Demonstrate Rapid Effectiveness Against Depression
TL;DR Summary
A mid-stage trial of Beckley Psytech's psychedelic therapy for treatment-resistant depression shows significant symptom reduction, boosting prospects for approval amid a shifting regulatory landscape for psychedelic drugs.
- Psychedelic therapy shows promise in mid-stage study in treatment-resistant depression STAT
- atai Life Sciences Announces $50 Million Private Placement Financing Yahoo Finance
- Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study Psychedelic Alpha
- Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger Fierce Biotech
- Psychedelic nasal spray shows promise against depression Financial Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
89%
236 → 27 words
Want the full story? Read the original article
Read on STAT